Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-001 in Glabellar Frown Lines
NCT02939326Phase 2Completed
- Sponsor
- Bonti
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trenibotulinumtoxinE in glabellar rhytides (8 arms), sponsored by Bonti. Primary endpoint: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale at 42 days. Started Dec 2016; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT02939326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939326.